Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult 21 to 64 years of age;~* 15≤AHI ≤ 50 on screening polysomnogram (PSG)~* ESS score ≥ 7~* Able to understand and complete informed consent and all study assessments and forms, presented in an English-speaking format;~* Women of child-bearing potential (WCBP) must have a negative urine pregnancy test. In addition sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable or implantable hormonal contraceptive; tubal ligation; intra-uterine devices; barrier contraceptive with spermicide; or vasectomized partner).~Exclusion Criteria:~* Arterial oxygen saturation \< 75% for \> 5% of sleep period time on screening PSG;~* Occupation or life situation that may impart risk by study participation (e.g. commercial driver, pilot, police officer, fireman);~* Motor vehicle accident or near-miss related to sleepiness (self-report) within 2 years of the first dose of study drug (Day 8);~* Body mass index \> 45 kg/m2~* Severe obstructive sleep apnea syndrome (OSAS) that, based on the clinical judgment of the Investigator, precludes delaying positive airway pressure treatment;~* History of shift work or rotating shifts within the month prior to the first dose of study drug (Day 8);~* Prior upper airway surgery for snoring or OSAS as an adult (≥ 18 years of age);~* Prior non-invasive treatment for OSAS within 6 months prior to the first dose of study drug (Day 8);~* Major surgery within 6 months prior to the first dose of study drug (Day 8);~* Bariatric surgery within 2 years prior to the first dose of study drug (Day 8). If post-bariatric surgery, weight must be stable ±5% (self-report) for at least 6 months prior to first dose of study drug (Day 8).~* Any form of medically managed weight loss program within 6 months prior to the first dose of study drug (Day 8);~* Significant defect in nasal patency due to anatomical abnormalities or uncontrolled or recurrent episodes of rhinitis;~* Any clinically significant unstable or progressive medical condition;~* Any primary sleep disorder other than OSAS as determined by history, physical examination, or Visit 2 PSG (after 7-day screening run-in period);~* Clinically significant or uncontrolled: chronic obstructive pulmonary disease (COPD), cardiovascular disease, gastrointestinal, respiratory, pancreatic, hepatic, renal, hematologic, endocrine \[including insulin-dependent diabetes mellitus (IDDM)\], neurological, urogenital, connective tissue, dermatological, thyroid, or other medical disorder;~* Any clinically significant psychiatric disorder;~* History of seizure disorder;~* Treatment with any prescription antidepressant medication within 1 month prior to the first dose of study drug (Day 8);~* Treatment with sedatives, hypnotics or other psychoactive drugs within 30 days prior to the first dose of study drug (Day 8);~* Any complete blood count (CBC) or liver function test (LFT) laboratory value outside the normal range which, in the clinical judgment of the Investigator renders a subject inappropriate for randomization to treatment;~* Pregnancy \[as demonstrated by positive urine human chorionic gonadotropin (hCG) test\] or lactation;~* Allergic to cannabinoids or sesame oil;~* History of substance abuse (including alcohol abuse or dependence) or laboratory evidence of drug abuse on the Visit 1 drug-screening panel;~* Use of dietary supplements which in the judgment of the Investigator may impact sleep or breathing behaviors;~* Average daily caffeine consumption \> 500 mg/day (\~5 cups of coffee);~* Average weekly alcohol consumption \> 10 units;~* Unwillingness to abstain from caffeine and alcohol on all days when overnight or daytime testing will be performed;~* Participation in any other investigational protocol within the 30 days prior to the first dose of study drug (Day 8);~* Any condition which, in the opinion of the Investigator, places the patient at unacceptable risk if he or she were to participate in the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Sugar Pill (Type: PLACEBO_COMPARATOR): Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
- 2.5 mg/day (Type: EXPERIMENTAL): Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
- 10 mg/day (Type: EXPERIMENTAL): Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation

Based on this trial design, predict the completion outcome and termination type (if applicable).